• Aliases: ACP-196; BTK inhibitor
    • An orally available inhibitor of BTK preventing the activation of the B-cell antigen receptor signaling pathway
    • FDA approved in October 2017 for MCL patients who have had one prior therapy.
    • Recommended dose: 100 mg PO Q 12 hours until progression
    • Metabolism: Avoid concomitant use with potent CYP3A4 inducers or inhibitors. May dose-adjust with moderate inhibitors of CYP3A4.
    • Half-life: 0.6 to 2.8 hours; ACP-5862 (active metabolite) â™6.9 hours
    • Side effects: Headache, fatigue, skin rash, diarrhea, bruise, neutropenia, myalgias, anemia, rare increase in serum creatinine
    Other topics in Targeted and Immunotherapy Agents